Navigation Links
Biopure Completes U.K. Regulatory Agency Inspection
Date:3/19/2008

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has completed its inspection of the company's Pennsylvania manufacturing facility. The inspection report contained no "Critical" and no "Major" deficiencies in compliance with good manufacturing practices. The MHRA report identified shortcomings characterized as "Other," with a request for a response detailing the company's corrective actions within 35 working days.

According to John Tomera, Director of Regulatory Affairs at Biopure, "We are pleased with the MHRA's inspection result, which attests to our efforts toward consistently maintaining quality standards. We anticipate being able readily to address all of the issues that were cited by the MHRA."

As previously announced, Biopure has pending with the MHRA a marketing authorization application to market Hemopure in the United Kingdom for acute anemia during elective orthopedic surgery where red blood cell transfusion is not available. The inspection is a routine part of the application procedure.

No inspection of the company's manufacturing facility in Massachusetts is scheduled at this time or expected to occur before the MHRA next communicates about the pending application.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Announces 2008 First Quarter Financial Results
2. Biopure Launches Updated Website
3. Biopure Announces Pricing of Equity Offering
4. Biopure Gives Update on Malaysia Joint Venture Discussions
5. Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing
6. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
7. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
8. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
9. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
10. Plurality Completes R&D of its HAL-256 Multicore Processor
11. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
(Date:2/11/2016)... 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... 2015. --> --> For ... of $29.3 million, or $0.34 loss per share, compared to a ... the same period in 2014. For the year ended December 31, ... $1.05 loss per share, as compared to a net loss of ...
(Date:2/11/2016)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical solutions ... of the Steering Committee for its Pelvic Mass Registry. ... Pelvic masses can present physicians and healthcare professionals with ... ruled out, pelvic masses may include cancers of the ... tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... , Germany and ... -- QGEN ; Frankfurt Prime Standard: QIA) ... QIAseq Targeted RNA Panels for gene expression profiling, expanding ... sequencing (NGS). The panels enable researchers to select from ... fold changes and discover interactions between genes, cellular phenotypes ...
Breaking Biology Technology:
(Date:2/11/2016)... -- According to new research from Acuity Market Intelligence, ... fingerprint, iris, and eye-vein biometric smartphones have been ... This includes market leaders Apple, Samsung, Huawei, Xiaomi, ... 600 million biometric smartphones are currently in use ... Maxine Most , Acuity Market Intelligence Principal, ...
(Date:2/11/2016)... LIVERMORE, Calif. , Feb. 11, 2016  Vigilant Solutions ... commercial LPR data are being used by Lee,s ... residents, including the recent location and arrest of a homicide ... Lee,s Summit covers around 65 square miles and ... Police Department has a single mobile license plate ...
(Date:2/10/2016)... February 10, 2016 ... to 2016 iris recognition market report, combined ... is more widely accepted for border control. ... fingerprint and iris recognition technology in a ... avoid purchasing two individual biometrics devices. ...
Breaking Biology News(10 mins):